<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954042</url>
  </required_header>
  <id_info>
    <org_study_id>Pelvital</org_study_id>
    <nct_id>NCT02954042</nct_id>
  </id_info>
  <brief_title>Pelvital Stress Urinary Incontinence Training Device: P-SUIT</brief_title>
  <official_title>Pelvital Stress Urinary Incontinence Training Device: P-SUIT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to compare the clinical benefits of using the Pelvital
      product, in comparison to a sham procedure as a noninvasive treatment for female incontinence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      120 subjects with SUI will be recruited into a randomized, double-blind, sham-controlled
      crossover trial. Subjects will be allocated in a 1:1 ratio (60 per arm) to either the control
      arm (PFMT) or the treatment arm (PFMT in conjunction with the Pelvital therapy). Subjects
      will conduct their respective therapy five minutes a day over the course of six weeks. At
      weeks two, four and six, the subjects will conduct bi-weekly check-ups. After six weeks, all
      patients in the control arm will have the option to cross over into the treatment arm if no
      improvement in symptoms has been shown.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in severity of involuntary urine loss</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Measured by pad testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incontinence episode frequency</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Daily Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Quality of Life questionarie</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Incontinence</condition>
  <arm_group>
    <arm_group_label>Pelvital probe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probe to use for incontinence-Pevital is company name of product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Probe</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo probe</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pelvital probe</intervention_name>
    <description>Pelvital probe</description>
    <arm_group_label>Pelvital probe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Probe</intervention_name>
    <description>Placebo Probe</description>
    <arm_group_label>Placebo Probe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female gender,

          2. Ages 18-75,

          3. Clinical diagnosis of stress urinary incontinence,

          4. Ability to contract the pelvic floor muscles,

          5. Able to document incontinence and voiding in a diary,

          6. Provision of written informed consent form,

          7. Minimum of 10 grams increase at initial 24-hour pad weight test

        Exclusion Criteria:

          1. Diagnosed mixed or urge urinary incontinence,

          2. Impaired cognitive function or neurologic conditions

          3. Physical limitations that impede the patient's ability to participate (e.g., ability
             to stand),

          4. Acute infections or hematuria,

          5. Pregnant or actively trying to conceive,

          6. History of pelvic irradiation,

          7. Concurrent medications with Î±-adrenergic antagonists or diuretics

          8. Pelvic organ prolapse stage III or IV,

          9. Severe urethral sphincter weakness and/or defect,

         10. Suspected urethral and/or vesical fistula
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nissrine Nakib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bethany Marlette</last_name>
    <phone>612-626-6661</phone>
    <email>marle025@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Maple Grove</city>
        <state>Minnesota</state>
        <zip>55369</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanne Ferguson</last_name>
      <phone>763-898-1714</phone>
      <email>fergu296@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Nissrine Nakib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro OBGYN</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emy Harrington</last_name>
      <phone>651-265-6770</phone>
      <email>eharrington@metro-obgyn.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Hallman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rjangvald Mjanger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Marlette</last_name>
      <phone>612-626-6661</phone>
      <email>marle025@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Nissrine Nakib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reba Blissell</last_name>
      <phone>206-616-8723</phone>
      <email>blissr@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Suzette Sutherland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

